cisplatin + etoposide + mitomycin + vindesine

This is a combination chemotherapy regimen consisting of four cytotoxic agents: cisplatin, etoposide, mitomycin, and vindesine. Each component has a distinct mechanism of action targeting cancer cells: - **Cisplatin** is a platinum-based compound that forms DNA crosslinks, inhibiting DNA synthesis and function. - **Etoposide** inhibits topoisomerase II, leading to DNA strand breaks and apoptosis. - **Mitomycin** acts as an alkylating agent causing DNA crosslinking and inhibition of DNA synthesis. - **Vindesine** is a vinca alkaloid that disrupts microtubule formation during cell division. This combination has been investigated primarily for the treatment of advanced or inoperable non-small-cell lung cancer (NSCLC), with studies comparing various combinations including these agents[1][2][3]. The rationale for combining these drugs is to exploit their complementary mechanisms to maximize antitumor efficacy.